epz-6438 and Sarcoma--Ewing

epz-6438 has been researched along with Sarcoma--Ewing* in 1 studies

Other Studies

1 other study(ies) available for epz-6438 and Sarcoma--Ewing

Article	Year
EZH2 Inhibition in Ewing Sarcoma Upregulates G Molecular therapy : the journal of the American Society of Gene Therapy, 2019, 05-08, Volume: 27, Issue:5 Chimeric antigen receptor (CAR) engineering of T cells allows one to specifically target tumor cells via cell surface antigens. A candidate target in Ewing sarcoma is the ganglioside G Topics: Antigens, Surface; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Enhancer of Zeste Homolog 2 Protein; Gangliosides; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Immunotherapy, Adoptive; Indoles; Morpholines; Promoter Regions, Genetic; Pyridones; Receptors, Chimeric Antigen; Sarcoma, Ewing; T-Lymphocytes	2019

Article

Year

EZH2 Inhibition in Ewing Sarcoma Upregulates G

Molecular therapy : the journal of the American Society of Gene Therapy, 2019, 05-08, Volume: 27, Issue:5

Chimeric antigen receptor (CAR) engineering of T cells allows one to specifically target tumor cells via cell surface antigens. A candidate target in Ewing sarcoma is the ganglioside G

Topics: Antigens, Surface; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Enhancer of Zeste Homolog 2 Protein; Gangliosides; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Immunotherapy, Adoptive; Indoles; Morpholines; Promoter Regions, Genetic; Pyridones; Receptors, Chimeric Antigen; Sarcoma, Ewing; T-Lymphocytes

2019